The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank
Executive Summary
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
You may also be interested in...
US Employers Say Government Drug Pricing Reforms Needed To Supplement Market-Based Efforts
Annual Business Group on Health survey on employer-sponsored insurance covers pricing reform, rebate model alternatives, paying for high-cost drugs and copay coupons.
Initial US Health Plan Disclosures On Drug Rebates And Patient Cost Sharing Postponed
Postponement of the transparency requirement established via late 2020 legislation may mean data from health plans may not be publicly available until 2024.
Medicare Part D Spending Projections Revised Downward Because Of Rebates – Trustees Report
Underscoring the importance of rebates to program financials, the trustees project a steep increase in Part D reinsurance payments over next decade.